🧬 AI-Designed Universal Coronavirus Vaccine Passes First Human Trial
Researchers at the University of Cambridge and their spinout DIOSynVax have just completed the first-ever human trial of a vaccine whose active ingredient was designed entirely by artificial intelligence. The results, published in the Journal of Infection, show the vaccine is safe, well-tolerated, and generates immune responses against not just one coronavirus — but an entire family of them.
Unlike traditional vaccines that chase after individual variants, this vaccine uses an AI-designed "super-antigen." Machine learning algorithms analysed genetic data from every known Sarbeco coronavirus — the family that includes SARS-CoV-2, SARS, and multiple bat coronaviruses with pandemic potential — and stitched together their shared molecular features into a single immune-training molecule. The result: one shot that teaches the body to recognise the whole family, including viruses that haven't jumped to humans yet.
The Phase 1 trial enrolled 39 healthy volunteers in Southampton and Cambridge. The vaccine was administered via a needle-free micro fluid jet — no syringes involved. Participants developed immune responses against SARS-CoV-2, the original SARS virus, and against bat coronaviruses flagged as future spillover risks. No significant side effects were reported.
— First AI-designed vaccine antigen ever tested in humans
— Single "super-antigen" targets the entire Sarbeco coronavirus family
— Needle-free delivery via micro fluid jet — no injections required
— Immune responses detected against SARS-CoV-2, SARS, and bat viruses with pandemic potential
— Same platform adaptable for Ebola, influenza, and other rapidly mutating viruses
"We've converted vaccine development from being reactive to being future-proof." — Professor Jonathan Heeney, Cambridge
Why it matters: By the time a vaccine is developed against a circulating strain, the virus has already evolved. This AI-driven approach builds immunity against entire virus families before the next outbreak begins. If it works across coronaviruses, Ebola, and influenza, it could fundamentally change how humanity prepares for pandemics.
📄 Journal of Infection: https://www.journalofinfection.com/article/S0163-4453(26)00084-8/fulltext
📖 ScienceDaily: https://www.sciencedaily.com/releases/2026/06/260605023357.htm
#UniversalVaccine #AIBiology #PandemicPreparedness #Coronavirus #FutureOfMedicine
Researchers at the University of Cambridge and their spinout DIOSynVax have just completed the first-ever human trial of a vaccine whose active ingredient was designed entirely by artificial intelligence. The results, published in the Journal of Infection, show the vaccine is safe, well-tolerated, and generates immune responses against not just one coronavirus — but an entire family of them.
Unlike traditional vaccines that chase after individual variants, this vaccine uses an AI-designed "super-antigen." Machine learning algorithms analysed genetic data from every known Sarbeco coronavirus — the family that includes SARS-CoV-2, SARS, and multiple bat coronaviruses with pandemic potential — and stitched together their shared molecular features into a single immune-training molecule. The result: one shot that teaches the body to recognise the whole family, including viruses that haven't jumped to humans yet.
The Phase 1 trial enrolled 39 healthy volunteers in Southampton and Cambridge. The vaccine was administered via a needle-free micro fluid jet — no syringes involved. Participants developed immune responses against SARS-CoV-2, the original SARS virus, and against bat coronaviruses flagged as future spillover risks. No significant side effects were reported.
— First AI-designed vaccine antigen ever tested in humans
— Single "super-antigen" targets the entire Sarbeco coronavirus family
— Needle-free delivery via micro fluid jet — no injections required
— Immune responses detected against SARS-CoV-2, SARS, and bat viruses with pandemic potential
— Same platform adaptable for Ebola, influenza, and other rapidly mutating viruses
"We've converted vaccine development from being reactive to being future-proof." — Professor Jonathan Heeney, Cambridge
Why it matters: By the time a vaccine is developed against a circulating strain, the virus has already evolved. This AI-driven approach builds immunity against entire virus families before the next outbreak begins. If it works across coronaviruses, Ebola, and influenza, it could fundamentally change how humanity prepares for pandemics.
📄 Journal of Infection: https://www.journalofinfection.com/article/S0163-4453(26)00084-8/fulltext
📖 ScienceDaily: https://www.sciencedaily.com/releases/2026/06/260605023357.htm
#UniversalVaccine #AIBiology #PandemicPreparedness #Coronavirus #FutureOfMedicine
Journal of Infection
A phase I, needle free, dose escalation clinical trial of pEVAC-PS, a candidate pan-Sarbecovirus Vaccine
Needle-free intradermal delivery of this novel computationally designed PanSarbeco
vaccine was safe and well tolerated. Although immunogenicity was modest in the context
of substantial pre-existing immunity, participants developed measurable responses
to…
vaccine was safe and well tolerated. Although immunogenicity was modest in the context
of substantial pre-existing immunity, participants developed measurable responses
to…
👍19🕊17👀17😁14🔥8